Netakimab - new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

• Main Authors: A. A. Kubanov (Author), A. L. Bakulev (Author), A. V. Samtsov (Author), V. R. Khairutdinov (Author), E. V. Sokolovskiy (Author), M. M. Kokhan (Author), A. V. Artemyeva (Author), E V. Chernyaeva (Author), R. A. Ivanov (Author)
• Format: Book
• Published: State Scientific Center of Dermatovenereology and Cosmetology, 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federation, registration certificate number ЛП-005439 fr...